Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Simeone, Ester ^a   De Maio, Eleonora ^a   Sandomenico, Fabio ^a   Fulciniti, Franco ^a   Lastoria, Secondo ^a   Aprea, Pasquale ^a   Staibano, Stefania ^b   Montesarchio, Vincenzo ^c   Palmieri, Giuseppe ^d   Mozzillo, Nicola ^a   Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; VEMURAFENIB;

ADULT; ADVANCED CANCER; ARTICLE; ASCITES; BRAIN METASTASIS; CANCER PATIENT; CASE REPORT; CEREBROSPINAL FLUID; COMA; CUTANEOUS MELANOMA; DISEASE COURSE; FEMALE; HUMAN; LEPTOMENINGEAL METASTASIS; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL;

EID: 84861079916     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-131     Document Type: Article

References (27)

1. Leptomeningeal metastases in the MRI era. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM, Neurology 2010 74 1449 1454 10.1212/WNL. 0b013e3181dc1a69 20439847
2. Leptomeningeal metastasis. Chamberlain MC, Curr Opin Oncol 2010 22 627 635 10.1097/CCO.0b013e32833de986 20689429
3. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Beauchesne P, Lancet Oncol 2010 11 871 900 10.1016/S1470-2045(10)70034-6 20598636
4. Improved survival with ipilimumab in patients with metastatic melanoma. Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ, N Engl J Med 2010 363 711 723 10.1056/NEJMoa1003466 20525992
5. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. Robert C, Thomas L, Bondarenko I, ODay S, JW MD, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD, N Engl J Med 2011 364 2517 2526 10.1056/NEJMoa1104621 21639810
6. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, ODay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur AG, BRIM-3 Study Group, N Engl J Med 2011 364 2507 2516 10.1056/NEJMoa1103782 21639808
7. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases [abstract]. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, Veronese ML, Nick S, Hilfiker P, Gobbi S, J Clin Oncol 2011 29 Suppl 18S 8548
8. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS, J Clin Oncol 2010 28 Suppl 18S 8503
9. Phase 1/2 Study of GSK2118436, a selective inhibitor of V600 mutant BRAF kinase: evidence of activity in melanoma brain metastases [abstract]. Long GV, Kefford RF, Carr PJA, Brown MP, Curtis M, Ma B, Lebowitz P, Kim KB, Kurzrock R, Flachook G, Ann Oncol 2010 21 Suppl 8S &22iii12
10. Italian Melanoma Intergroup (IMI): Mutation frequency inBRAFandNRASgenes among primary tumors and different types of metastasis from melanoma patients [abstract]. Colombino M, Capone M, Maio M, De Giorgi V, Cossu A, Lissia A, Rubino C, Massidda B, Staibano S, Nappi O, Botti G, Caraco C, Mozzillo N, Manca A, Sini M, Ascierto PA, Palmieri G, J Clin Oncol 2011 29 Suppl 18S 8574
11. A study of GSK2118436 in BRAF mutant metastatic melanoma to the brain (Break MB) http://clinicaltrials.gov/ct2/show/NCT01266967
12. A study of vemurafenib in metastatic melanoma patients with brain metastases, http://clinicaltrials.gov/ct2/show/NCT01378975
13. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE, Eur J Clin Invest 2003 33 76 81 10.1046/j.1365-2362.2003.01056.x 12492456 (Pubitemid 36051295)
14. Constitutive integrin activation on tumor cells contributes to progression of leptomeningeal metastases. Brandsma D, Ulfman L, Reijneveld JC, Bracke M, Taphoorn MJ, Zwaginga JJ, Gebbink MF, de Boer H, Koenderman L, Voest EE, Neuro Oncol 2006 8 127 136 10.1215/15228517-2005-013 16533879 (Pubitemid 46542657)
15. Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase. Katagiri K, Hattori M, Minato N, Irie S, Takatsu K, Kinashi T, Mol Cell Biol 2000 20 1956 1969 10.1128/MCB.20.6.1956-1969.2000 10688643 (Pubitemid 30123812)
16. The small GTPase, Rap1, mediates CD31-induced integrin adhesion. Reedquist KA, Ross E, Koop EA, Wolthuis RM, Zwartkruis FJ, van Kooyk Y, Salmon M, Buckley CD, Bos JL, J Cell Biol 2000 148 1151 1158 10.1083/jcb.148.6.1151 10725328
17. Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow. Shimonaka M, Katagiri K, Nakayama T, Fujita N, Tsuruo T, Yoshie O, Kinashi T, J Cell Biol 2003 161 417 427 10.1083/jcb.200301133 12707305 (Pubitemid 36529858)
18. Activating mutations of theGNAQgene: a frequent event in primary melanocytic neoplasms of the central nervous system. Küsters-Vandevelde HV, Klaasen A, Küsters B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger G, Wesseling P, Blokx WA, Acta Neuropathol 2010 119 317 323 10.1007/s00401-009-0611-3 19936769
19. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS, Nature 2010 468 973 977 10.1038/nature09626 21107323
20. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J, Cancer Res 2008 68 4853 4861 10.1158/0008-5472.CAN-07-6787 18559533
21. Melanoma-an unlikely poster child for personalized cancer therapy. Smalley KS, Sondak VK, N Engl J Med 2010 363 876 878 10.1056/NEJMe1005370 20818849
22. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA, J Clin Oncol 2011 29 3085 3096 10.1200/JCO.2010.33.2312 21383288
23. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA, Nature 2010 468 968 972 10.1038/nature09627 21107320
24. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, DAndrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M, Cancer Cell 2010 18 683 695 10.1016/j.ccr.2010.11.023 21156289
25. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM) [abstract]. Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I, J Clin Oncol 2011 29 Suppl 18S 8519
26. Combination therapy: the next opportunity and challenge of medicine. Ascierto PA, Marincola FM, J Transl Med 2011 9 115 10.1186/1479-5876-9-115 21777474
27. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]. Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris HA, Kim KB, Clements A, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT, J Clin Oncol 2011 29 Suppl 18S 8503